UY38546A - GPRC5D CHEMERIC ANTIGEN RECEPTORS AND CELLS THAT EXPRESS THEM - Google Patents
GPRC5D CHEMERIC ANTIGEN RECEPTORS AND CELLS THAT EXPRESS THEMInfo
- Publication number
- UY38546A UY38546A UY0001038546A UY38546A UY38546A UY 38546 A UY38546 A UY 38546A UY 0001038546 A UY0001038546 A UY 0001038546A UY 38546 A UY38546 A UY 38546A UY 38546 A UY38546 A UY 38546A
- Authority
- UY
- Uruguay
- Prior art keywords
- gprc5d
- cells
- antigen receptors
- express
- chemeric
- Prior art date
Links
- 102000006306 Antigen Receptors Human genes 0.000 title 1
- 108010083359 Antigen Receptors Proteins 0.000 title 1
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 title 1
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente descripción proporciona receptores de antígenos quiméricos (CAR) que se dirigen específicamente a un receptor acoplado a proteínas G, el miembro D del grupo 5 de la familia C de receptores acoplados a proteínas G (GPRC5D), y las células inmunosensibles que comprenden tales CAR, para el tratamiento del cáncerThe present disclosure provides chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, member D of group 5 of the G-protein coupled receptor C family (GPRC5D), and immunosensitive cells comprising such CAR, for the treatment of cancer
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962793973P | 2019-01-18 | 2019-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38546A true UY38546A (en) | 2020-07-31 |
Family
ID=69191097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038546A UY38546A (en) | 2019-01-18 | 2020-01-17 | GPRC5D CHEMERIC ANTIGEN RECEPTORS AND CELLS THAT EXPRESS THEM |
Country Status (20)
Country | Link |
---|---|
US (2) | US12077592B2 (en) |
EP (1) | EP3911677A1 (en) |
JP (2) | JP7303314B2 (en) |
KR (1) | KR20210116562A (en) |
CN (2) | CN113597433A (en) |
AR (1) | AR119676A1 (en) |
AU (1) | AU2020209257A1 (en) |
BR (1) | BR112021013824A2 (en) |
CA (1) | CA3127025A1 (en) |
CL (1) | CL2021001883A1 (en) |
CO (1) | CO2021010075A2 (en) |
EA (1) | EA202191939A1 (en) |
EC (1) | ECSP21060675A (en) |
IL (1) | IL284744A (en) |
JO (1) | JOP20210194A1 (en) |
MX (1) | MX2021008652A (en) |
PE (1) | PE20211977A1 (en) |
SG (1) | SG11202107708XA (en) |
UY (1) | UY38546A (en) |
WO (1) | WO2020148677A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202191939A1 (en) | 2019-01-18 | 2021-10-12 | Янссен Байотек, Инк. | CHIMERIC ANTIGENIC GPRC5D RECEPTORS AND EXPRESSING THEIR CELLS |
US12030937B2 (en) | 2020-07-17 | 2024-07-09 | Janssen Biotech, Inc. | Anti-idiotypic antibodies against anti-GPRC5D antibodies |
WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
AU2022201736B2 (en) * | 2021-01-05 | 2023-03-16 | Lanova Medicines Development Co., Ltd. | Anti-GPRC5D monoclonal antibodies and uses thereof |
JP2024507180A (en) | 2021-02-16 | 2024-02-16 | ヤンセン ファーマシューティカ エヌ.ベー. | Trispecific antibody targeting BCMA, GPRC5D, and CD3 |
CN115386010A (en) * | 2021-05-23 | 2022-11-25 | 上海邦耀生物科技有限公司 | Chimeric antigen receptor targeting GPRC5D and application thereof |
TW202317619A (en) * | 2021-06-01 | 2023-05-01 | 美商健生生物科技公司 | Anti-idiotypic antibodies against anti-cd79b antibodies |
JP2024533162A (en) * | 2021-09-02 | 2024-09-12 | メモリアル スローン ケタリング キャンサー センター | Anti-CD33 antibodies and uses thereof |
US20230134748A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
EP4428153A1 (en) * | 2021-11-05 | 2024-09-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibody binding to gprc5d and use thereof |
WO2023173272A1 (en) * | 2022-03-15 | 2023-09-21 | 上海驯鹿生物技术有限公司 | Gprc5d-targeting fully humanized chimeric antigen receptor (car) and use thereof |
WO2023125888A1 (en) * | 2021-12-31 | 2023-07-06 | 山东先声生物制药有限公司 | Gprc5d antibody and application thereof |
CN116375867A (en) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | anti-GPRC 5D antibody and application thereof |
AU2023207739A1 (en) * | 2022-01-14 | 2024-08-29 | Oricell Therapeutics Co., Ltd. | Chimeric antigen receptor targeting gprc5d and use thereof |
WO2023227062A1 (en) * | 2022-05-27 | 2023-11-30 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof |
WO2024017362A1 (en) * | 2022-07-22 | 2024-01-25 | 上海先博生物科技有限公司 | Chimeric antigen receptor targeting gprc5d and/or bcma, and use thereof |
WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
CN116003598B (en) * | 2022-08-30 | 2024-04-26 | 苏州缔码生物科技有限公司 | Recombinant humanized monoclonal antibody targeting human GPRC5D and application thereof |
WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
CN116751310B (en) * | 2023-06-13 | 2024-02-13 | 广东省第二人民医院(广东省卫生应急医院) | Chimeric antigen receptor targeting CD19 and GPRC5D ligand and application thereof |
CN117229407B (en) * | 2023-11-14 | 2024-02-20 | 成都优赛诺生物科技有限公司 | Single-domain antibody targeting GPRC5D, chimeric antigen receptor and application thereof |
CN118108846A (en) * | 2024-02-04 | 2024-05-31 | 四川大学华西医院 | Preparation and application of targeted GPRC5D allogeneic CAR-gamma delta T cells |
CN117700558B (en) * | 2024-02-06 | 2024-05-03 | 苏州艾凯利元生物科技有限公司 | Monoclonal anti-GPRC 5D antibody and anti-GPRC 5D-CAR-NK cell |
CN118325927A (en) * | 2024-06-13 | 2024-07-12 | 广州安捷生物医学技术有限公司 | Polynucleotides encoding NK cell adaptors and CARs and modified cells comprising same |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IT1229106B (en) | 1989-04-05 | 1991-07-18 | Armando Bigarella | "SPLIT" TYPE TRANSFERABLE ROOM CONDITIONER. |
DK0546073T3 (en) | 1990-08-29 | 1998-02-02 | Genpharm Int | Production and use of transgenic, non-human animals capable of forming heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
JPH04167172A (en) | 1990-10-31 | 1992-06-15 | Nec Corp | Vector processor |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
CA2398136A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
TWI544076B (en) | 2005-03-31 | 2016-08-01 | Chugai Pharmaceutical Co Ltd | A method of manufacturing a polypeptide that controls assembly |
DK1999154T3 (en) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | MANUFACTURED HETERODIMERED PROTEIN DOMAINS |
JP2009541275A (en) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | Production of bispecific antibodies |
EP2139924B1 (en) | 2007-03-29 | 2016-07-06 | Genmab A/S | Bispecific antibodies and methods for production thereof |
ES2564523T3 (en) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Design and generation of phage de novo human presentation libraries by fusion with pIX or pVII, vectors, antibodies and methods |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
CN102459346B (en) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | The method manufacturing heteromultimers molecule |
JO3246B1 (en) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | High affinity human antibodies to human protease-activated receptor-2 |
CA2796181C (en) | 2010-04-20 | 2023-01-03 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
EP2635607B1 (en) | 2010-11-05 | 2019-09-04 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
US9272002B2 (en) * | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
KR102612367B1 (en) * | 2014-12-05 | 2023-12-12 | 메모리얼 슬로안 케터링 캔서 센터 | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
EP3324984A4 (en) * | 2015-07-21 | 2019-03-27 | City of Hope | T cells for expression of chimeric antigen receptors and other receptors |
US10776517B2 (en) * | 2016-06-10 | 2020-09-15 | OneTrust, LLC | Data processing systems for calculating and communicating cost of fulfilling data subject access requests and related methods |
TWI781108B (en) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof |
EP3581651A4 (en) | 2017-02-07 | 2021-05-12 | Daiichi Sankyo Company, Limited | Anti-gprc5d antibody and molecule containing same |
KR20230007557A (en) | 2017-09-22 | 2023-01-12 | 카이트 파마 인코포레이티드 | Chimeric polypeptides and uses thereof |
WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
WO2020109953A1 (en) * | 2018-11-30 | 2020-06-04 | Janssen Biotech, Inc. | Gamma delta t cells and uses thereof |
EA202191939A1 (en) | 2019-01-18 | 2021-10-12 | Янссен Байотек, Инк. | CHIMERIC ANTIGENIC GPRC5D RECEPTORS AND EXPRESSING THEIR CELLS |
JP2024507180A (en) * | 2021-02-16 | 2024-02-16 | ヤンセン ファーマシューティカ エヌ.ベー. | Trispecific antibody targeting BCMA, GPRC5D, and CD3 |
-
2020
- 2020-01-15 EA EA202191939A patent/EA202191939A1/en unknown
- 2020-01-15 CN CN202080022394.4A patent/CN113597433A/en active Pending
- 2020-01-15 US US16/743,188 patent/US12077592B2/en active Active
- 2020-01-15 CA CA3127025A patent/CA3127025A1/en active Pending
- 2020-01-15 PE PE2021001193A patent/PE20211977A1/en unknown
- 2020-01-15 JO JOP/2021/0194A patent/JOP20210194A1/en unknown
- 2020-01-15 AU AU2020209257A patent/AU2020209257A1/en active Pending
- 2020-01-15 JP JP2021541185A patent/JP7303314B2/en active Active
- 2020-01-15 MX MX2021008652A patent/MX2021008652A/en unknown
- 2020-01-15 CN CN202410601046.2A patent/CN118459611A/en active Pending
- 2020-01-15 BR BR112021013824A patent/BR112021013824A2/en unknown
- 2020-01-15 EP EP20701897.9A patent/EP3911677A1/en active Pending
- 2020-01-15 KR KR1020217025965A patent/KR20210116562A/en active Search and Examination
- 2020-01-15 WO PCT/IB2020/050310 patent/WO2020148677A1/en unknown
- 2020-01-15 SG SG11202107708XA patent/SG11202107708XA/en unknown
- 2020-01-17 UY UY0001038546A patent/UY38546A/en unknown
- 2020-01-17 AR ARP200100123A patent/AR119676A1/en unknown
-
2021
- 2021-07-11 IL IL284744A patent/IL284744A/en unknown
- 2021-07-15 CL CL2021001883A patent/CL2021001883A1/en unknown
- 2021-07-29 CO CONC2021/0010075A patent/CO2021010075A2/en unknown
- 2021-08-17 EC ECSENADI202160675A patent/ECSP21060675A/en unknown
-
2023
- 2023-06-22 JP JP2023102126A patent/JP2023130380A/en active Pending
-
2024
- 2024-04-23 US US18/643,356 patent/US20240262921A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3127025A1 (en) | 2020-07-23 |
TW202043263A (en) | 2020-12-01 |
AR119676A1 (en) | 2022-01-05 |
CO2021010075A2 (en) | 2021-08-19 |
AU2020209257A1 (en) | 2021-08-05 |
EP3911677A1 (en) | 2021-11-24 |
CN113597433A (en) | 2021-11-02 |
SG11202107708XA (en) | 2021-08-30 |
MX2021008652A (en) | 2021-10-26 |
PE20211977A1 (en) | 2021-10-05 |
WO2020148677A1 (en) | 2020-07-23 |
CL2021001883A1 (en) | 2022-01-21 |
CN118459611A (en) | 2024-08-09 |
KR20210116562A (en) | 2021-09-27 |
IL284744A (en) | 2021-08-31 |
JP7303314B2 (en) | 2023-07-04 |
BR112021013824A2 (en) | 2021-12-14 |
ECSP21060675A (en) | 2021-09-30 |
JP2023130380A (en) | 2023-09-20 |
EA202191939A1 (en) | 2021-10-12 |
JOP20210194A1 (en) | 2023-01-30 |
JP2022518708A (en) | 2022-03-16 |
US20200231686A1 (en) | 2020-07-23 |
US20240262921A1 (en) | 2024-08-08 |
US12077592B2 (en) | 2024-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38546A (en) | GPRC5D CHEMERIC ANTIGEN RECEPTORS AND CELLS THAT EXPRESS THEM | |
CL2021001686A1 (en) | Single Domain Antibody-Based Chimeric Antigen Receptors and Methods of Using Them (Divisional Application No. 201800378) | |
ECSP18038868A (en) | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST | |
CL2017001090A1 (en) | Heterodimeric immunoglobulins of redirection of t-cells cd3 / cd38 and their production methods | |
BR112022008522A2 (en) | USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | |
CL2019002314A1 (en) | Aryl hydrocarbon receptor (ahr) modulating compounds. | |
BR112016022727A8 (en) | claudin-6 specific immunoreceptors and t-cell epitopes | |
CO2018013298A2 (en) | Anti-gitr antibodies and their uses. | |
CO2019013654A2 (en) | Chimeric antigen receptors targeting flt3 | |
CL2019002011A1 (en) | Anti-tgf-beta antibodies and their use. | |
PE20160716A1 (en) | ANTI-TWEAKR ANTIBODY AND ITS USES | |
CL2019002112A1 (en) | Aryl hydrocarbon receptor (ahr) modulating compounds. | |
CO2021010347A2 (en) | Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers | |
CO2022000705A2 (en) | Chimeric antigen receptor (car) anti-hk2 | |
CL2022001299A1 (en) | Anti-cd79 chimeric antigen receptors, car-t cells and their uses. | |
DOP2022000014A (en) | ANTI-HK2 CHIMERIC ANTIGEN RECEPTOR (CAR) | |
AR119469A1 (en) | ANTI-HK2 CHIMERIC ANTIGEN RECEPTOR (CAR) | |
AR116045A1 (en) | METHODS FOR PREPARING CELLS THAT EXPRESS RECEPTORS OF CHIMERIC ANTIGENS | |
AR115534A1 (en) | BCMA CHEMERICAL ANTIGEN RECEPTORS AND USES OF THEM | |
CR20210382A (en) | Gprc5d chimeric antigen receptors and cells expressing the same |